RNA-Targeting Drugs: A Latest Frontier in Pharmaceutical Innovation

For decades, drug discovery has largely focused on proteins. However, as traditional protein targets become saturated, a new approach is gaining momentum: targeting RNA. This shift promises innovative therapies for a range of diseases, particularly rare conditions and cancers, and is attracting significant investment from pharmaceutical companies.

The Rise of RNA-Based Therapeutics

While tiny molecule drugs have long been the cornerstone of the pharmaceutical industry, there’s a growing demand for precision medicine, often associated with biologic therapies. RNA-based therapeutics have already demonstrated success. Ionis Pharmaceuticals’ Spinraza (nusinersen), approved in 2016, treats spinal muscular atrophy (SMA) with an antisense oligonucleotide (ASO). Alnylam Pharmaceuticals’ Onpattro (patisiran), the first RNA interference (RNAi) therapeutic, gained approval in 2018. The significance of RNA research was further underscored in 2024 with the Nobel Prize in Physiology or Medicine awarded for the discovery of microRNA (miRNA) and its role in gene regulation.

Why RNA? Addressing the Limitations of Traditional Approaches

Traditional protein targets are becoming increasingly saturated, driving interest in alternative approaches [1]. RNA-based therapeutics, however, have faced challenges related to delivery, due to the large, hydrophilic nature of RNA and its susceptibility to degradation. RNA-targeting small molecules offer a potential solution, combining the benefits of transcription-level intervention with the advantages of oral availability and scalable manufacturing.

Challenges and Advancements in RNA-Targeting Drug Discovery

Historically, RNA has been considered a tough target for small molecules due to its dynamic structure and relative instability compared to proteins. However, advances in understanding RNA structural biology and the development of high-throughput screening techniques are enabling the identification of RNA-small molecule interactions. The current focus is on enhancing RNA selectivity, ensuring that drugs bind to the intended RNA target and minimize off-target effects [1].

Industry Collaboration and Investment

The pharmaceutical industry is increasingly recognizing the potential of RNA-targeting small molecules. Several significant partnerships have been formed recently:

• Merck KGaA & Skyhawk Therapeutics (2025): A collaboration valued at up to $2 billion [1].
• Daiichi Sankyo & Wayfinder Biosciences (2025): A partnership focused on using Wayfinder’s drug discovery platform for neurodegenerative diseases [1].
• Astellas Pharma & xFOREST Therapeutics (2025): Collaboration to utilize xFOREST’s RNA splicing-targeted drug discovery platform [1].
• Remix Therapeutics & Johnson & Johnson: Remix secured $45 million upfront for exclusive rights to three targets in immunology and oncology, with potential payments exceeding $1 billion [1].
• Remix Therapeutics & Roche (2024): A partnership for the discovery and development of small molecule therapeutics modulating RNA processing, including a $30 million upfront payment and potential milestone payments up to $1.12 billion [1].

Discovery Platforms and Technologies

Several platforms are driving progress in RNA-targeted drug discovery:

• xFOREST Therapeutics: Utilizes MatrixFOREST to identify druggable pockets within 3D RNA structures and SpliceVerse to identify regions prone to mis-splicing [1].
• Remix Therapeutics: Employs its REMaster platform, incorporating functional screening assays and machine learning to identify targetable mRNA exon sites and assess their impact on gene and protein expression [1].

Computational sciences, including artificial intelligence (AI), are playing an increasingly important role, enhancing computational approaches and accelerating discovery as larger, high-quality datasets become available [2], [3], [4].

Clinical Progress

Several RNA-targeting drugs are currently in clinical trials:

• Remix’s REM-422: Being studied in Phase I trials for adenoid cystic carcinoma and acute myeloid leukemia/myelodysplastic syndromes, targeting the MYB transcription factor [1].
• Skyhawk’s SKY-0515: Undergoing a Phase II/III trial (FALCON-HD) for Huntington’s disease, demonstrating improvements in disease rating scales in a Phase I trial [1].

Future Directions

Despite the progress, challenges remain, particularly regarding drug selectivity and safety. The dynamic nature of RNA increases the risk of off-target effects and toxicity. Continued innovation in RNA structure determination, computational modeling, and screening techniques will be crucial. The field is poised for continued growth, with the potential to unlock new therapeutic avenues for a wide range of diseases [3], [4].